Abstract:Introduction: The etiology of benign prostatic hyperplasia (BPH) has not so far been fully explicated. However, it is assumed that changes in the levels of hormones associated with aging can contribute to the development of prostatic hyperplasia. Dihydrotestosterone combines with the androgen receptor (AR) proteins of the prostate gland. Enzyme activity is based on two isoenzymes: type 1 and type 2. 5α-reductase type 1 is encoded by the SRD5A1 gene, and type 2 is encoded by the SRD5A2 gene. The aim of our study was to determine the frequency of the SRD5A1 (rs6884552, rs3797177) and SRD5A2 (rs523349, rs12470143) genes' polymorphisms, and to assess the relationships between the genotypes of the tested mutations, and the levels of biochemical and hormonal parameters in patients with BPH. Material and Methods: The study involved 299 men with benign prostatic hyperplasia. We determined the serum levels of particular biochemical parameters-fasting plasma glucose (FPG), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides (TG)-by the spectrophotometric method, using ready reagent kits. The ELISA method was used to determine the levels of the following hormonal parameters and proteins: total testosterone (TT), free testosterone (FT), insulin (I), luteinizing hormone (LH), and sex hormone binding protein (SHBG). Metabolic syndrome was diagnosed. Genotyping was performed by real-time PCR. Results: We analyzed the relationships between the incidence of particular diseases and the genotypes of the SRD5A1 and SRD5A2 polymorphisms among patients with BPH. The BPH patients with the CC genotype of the SRD5A2 rs523349 and rs12470143 polymorphisms were considerably less frequently diagnosed with metabolic syndrome (MetS) (p = 0.022 and p = 0.023 respectively). Our analysis revealed that homozygotes with the CC of the SDR5A2 rs12470143 polymorphism had visibly higher HDL levels than those with the TT and CT genotypes (p = 0.001). Additionally, we found that the patients with the CC genotype of the SDR5A2 rs12470143 polymorphism had considerably higher FT levels (p = 0.001) than the heterozygotes with the CT and the homozygotes with the TT of the genetic variant analyzed in our study. Furthermore, the patients with at least one G allele of the SRD5A2 rs523349 polymorphism had significantly lower SGBG levels (p = 0.022) compared with the homozygotes with the CC genotype. The presence of at least one A allele (AA + AG genotypes) of the SRD5A1 rs3797177 polymorphism entailed notably lower serum insulin levels than those observed in homozygotes with the GG genotype (p = 0.033). Conclusions: The study described in this article shows that selected SRD5A1 and SRD5A2 polymorphisms can alter the levels of metabolic and hormonal parameters in patients with BPH. Special attention should be paid to the SDR5A2 rs12470143 polymorphism, which is associated with a change in lipid profile, as well as with the inheritance and incidence rate of MetS among these patients. An analysis of the frequency of this polymorphism among BPH patients could be useful in estimating the risk of getting ill, and planning therapies of concomitant diseases for BPH patients.

SRD5A1 and SRD5A2 Are Associated with Treatment for Benign Prostatic Hyperplasia with the Combination of 5Α-Reductase Inhibitors and Α-Adrenergic Receptor Antagonists

Association Between SRD5A2 Rs523349 and Rs9282858 Polymorphisms and Risk of Benign Prostatic Hyperplasia: A Meta-Analysis

Genetic Variants in 5p13.2 and 7q21.1 Are Associated with Treatment for Benign Prostatic Hyperplasia with the Α-Adrenergic Receptor Antagonist.

Polymorphic Markers in the SRD5A2 Gene and Prostate Cancer Risk

Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels

Relationship between SRD5A2 rs9282858 polymorphism and the susceptibility of prostate cancer

[Association of Polymorphisms in Testosterone 5-Alpha-reductase II Genotype and Prognosis Factors of Prostate Cancer].

Meta-analysis of Three Polymorphisms in the Steroid-5-alpha-reductase, Alpha Polypeptide 2 Gene (SRD5A2) and Risk of Prostate Cancer

Association of CCL2, CCR2 and CCL5 Genetic Polymorphisms with the Development and Progression of Benign Prostatic Hyperplasia.

Clinical Significance Of Single Nucleotide Polymorphisms Of Adiponectin Gene In Chinese Benign Prostatic Hyperplasia Patients

Steroid 5-Alpha-reductase Type 2 ( SRD5A2 ) V89L and A49T Polymorphisms and Sporadic Prostate Cancer Risk: a Meta-Analysis

MP44-05 EARLY-ONSET SYMPTOMATIC BPH TISSUES OF MEN LESS THAN OR EQUAL TO 50 YEARS OLD APPEARED TO BE INCREASED STROMAL COMPONENTS AND VASCULARITY

Identification of Three Novel SRD5A2 Mutations in Chinese Patients with 5Α-Reductase 2 Deficiency.

Association of a Common Variant at 10q26 and Benign Prostatic Hyperplasia Aggressiveness in Han Chinese Descent.

Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis

Clinical and molecular characterization of 5α-reductase type 2 deficiency due to mutations (p.Q6X, p.R246Q) in SRD5A2 gene.

AB215. Variants in the SRD5A2 Gene Are Associated with Quality of Semen

Association between A49T polymorphism of SRD5A2 gene and risk of prostate cancer]

Enhanced prostatic Esr1+ luminal epithelial cells in the absence of SRD5A2

Efficacy of 5Α-Reductase Inhibitors for Patients with Large Benign Prostatic Hyperplasia (>80 Ml) after Transurethral Resection of the Prostate

Clinical, Hormonal, and Genetic Characteristics of 5a-Reductase Type 2 Deficiency in 103 Chinese Patients